March 22nd 2023
Antibody-drug conjugates, including those targeting PSMA, are among the next wave of treatment advances in mCRPC.
Trial of 64Cu SAR-bisPSMA in biochemically recurrent prostate cancer hits enrollment goalFebruary 9th 2023
"We are very pleased to have reached our recruitment target for the COBRA trial. The data generated thus far on the SAR-bisPSMA product is very encouraging and shows high uptake of the agent by prostate cancer cells,” said Neal Shore, MD.
MRI-based screening emerging as viable alternative to PSA testingDecember 7th 2022
“MRI-based screening showed lower proportions of screening-positive cases, lower false positive rates, and higher PPVs [positive predictive values] than those of PSA-based screening,” noted Taek Min Kim, MD.
177Lu-PSMA-617 significantly improves rPFS in earlier mCRPC settingDecember 6th 2022
According to Novartis, the developer of 177Lu-PSMA-617, the PSMAfore study is the first clinical trial of a PSMA-targeted radioligand therapy to demonstrate a clinically meaningful benefit in the pre–taxane-based chemotherapy mCRPC setting.
Potential biomarkers emerge for 177Lu-PSMA-617 in metastatic prostate cancerNovember 14th 2022
177Lu-PSMA-617 is approved by the FDA for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post taxane-based chemotherapy setting.
Expert explains everything you need to know about lutetium Lu-177 vipivotide tetraxetan for mCRPCOctober 28th 2022
"During treatment with 177Lu-PSMA-617, patients should be counseled to increase oral fluid intake and to void frequently to reduce bladder radiation exposure," writes Stephanie Trexler, PharmD, BCOP.
Urology Times 50 Innovations Series: Multiparametric MRI in prostate cancerOctober 5th 2022
“From a screening perspective, mpMRI really has changed how we evaluate men at risk for prostate cancer. It has improved the selection of men for biopsy and certainly improved our diagnostic rates,” says William P. Parker, MD.
UCSF investigators improve MR-guided TRUS fusion biopsy for prostate cancer detection using HP 13C MRIOctober 4th 2022
"HP 13C MRI provides a quick five-minute, non-radioactive, metabolic imaging add-on exam to standard-of-care MRI that, in conjunction with guided biopsies, has great potential to improve the care of prostate cancer patients,” said Robert Bok, MD, PhD.